ANIP logo

ANI Pharmaceuticals Inc. (ANIP)

$78.25

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on ANIP

Market cap

$1.76B

EPS

4.03

P/E ratio

19.4

Price to sales

1.9

Dividend yield

--

Beta

0.443035

Price on ANIP

Previous close

$82.63

Today's open

$77.09

Day's range

$74.33 - $78.59

52 week range

$67.98 - $99.50

Profile about ANIP

CEO

Nikhil Lalwani

Employees

642

Headquarters

Princeton, NJ

Exchange

NASDAQ Global Market

Shares outstanding

22458168

Issue type

Common Stock

ANIP industries and sectors

Healthcare

Pharmaceuticals

News on ANIP

ANI Pharmaceuticals Q2 Earnings Call Highlights

ANI Pharmaceuticals NASDAQ: ANIP reported record second-quarter revenue and adjusted EBITDA as growth in its Cortrophin Gel rare-disease franchise and generics business lifted results, while the company modestly reduced its full-year Cortrophin revenue outlook to reflect first-half performance.

news source

MarketBeat • Aug 7, 2026

news preview

ANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call Transcript

ANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call Transcript

news source

Seeking Alpha • Aug 7, 2026

news preview

ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Results

Quarterly net revenues of $266.0 million, an increase of 25.9% year-over-year Purified Cortrophin ® Gel net revenues of $117.1 million, an increase of 43.5% year-over-year Quarterly GAAP net income available to common shareholders of $24.7 million; Quarterly adjusted non-GAAP EBITDA of $71.6 million, an increase of 32.4% year-over-year Diluted GAAP income per share of $1.05 and adjusted non-GAAP diluted earnings per share of $2.21 Reaffirming 2026 guidance for total net revenue of $1,080 - $1,140 million and adjusted non-GAAP EBITDA of $285 - $300 million PRINCETON, N.J., Aug. 07, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced financial results and business highlights for the second quarter ended June 30, 2026.

news source

GlobeNewsWire • Aug 7, 2026

news preview

ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Beat Estimates

ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $2.21 per share, beating the Zacks Consensus Estimate of $2.01 per share. This compares to earnings of $1.8 per share a year ago.

news source

Zacks Investment Research • Aug 7, 2026

news preview

Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for ANI (ANIP) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

news source

Zacks Investment Research • Aug 7, 2026

news preview

ANI Pharmaceuticals: The Market Is Pricing The Present, Not The Future

ANI Pharmaceuticals is rated Buy at ~$80, with a 12-month fair value set at $95, as the current valuation undervalues 2027 earnings potential. 2026 results are depressed by upfront gout expansion costs and higher Corticotrophin royalties, but revenue and operating leverage from these investments are expected to materialize in 2027. Most 2026 Cortrophin growth is projected from established indications, not the new gout initiative, which is viewed as a 2027 upside driver.

news source

Seeking Alpha • Aug 6, 2026

news preview

ANI Pharmaceuticals (ANIP) Reports Next Week: Wall Street Expects Earnings Growth

ANI (ANIP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

news source

Zacks Investment Research • Jul 31, 2026

news preview

ANI Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 7, 2026 at 8:00 a.m. ET

PRINCETON, N.J., July 24, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that the Company will release its second quarter 2026 financial results on Friday, August 7, 2026, at 8:00 a.m. ET.

news source

GlobeNewsWire • Jul 24, 2026

news preview

Trump's generic drug tariffs: What they could mean for medicine prices, manufacturers and supply

Trump plans tariffs of up to 200% on imported generic drugs after a two-year grace period aimed at encouraging U.S. manufacturing. But thin profit margins make tariffs harder to absorb than for branded medicines and and key policy details remain unclear.

news source

CNBC • Jul 22, 2026

news preview

ANI Pharmaceuticals Announces Intent to Appeal Rulings in CG Oncology Matter

PRINCETON, N.J., July 16, 2026 (GLOBE NEWSWIRE) -- ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) (ANI or the Company) today announced that Judge Sheldon K. Rennie, on July 16, 2026, denied ANI's post-trial motions for a new trial and judgment as a matter of law. ANI intends to appeal to the Delaware Supreme Court and continue to seek to recover the value of the assets it sold to CG Oncology under the 2010 Agreement between the parties.

news source

GlobeNewsWire • Jul 16, 2026

news preview

¹ Disclosures

Get started with M1

Invest in ANI Pharmaceuticals Inc.

Open an M1 investment account to buy and sell ANI Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in ANIP on M1